Copegus

COPEGUS ribavirin, USP ; You have a liver disease called autoimmune hepatitis hepatitis caused by your immune system attacking your liver ; . You have unstable or advanced liver disease. You are allergic to any of the ingredients in COPEGUS. The active ingredient in COPEGUS is ribavirin. See the end of this Medication Guide for a list of all the ingredients in COPEGUS. Tell your healthcare provider before starting treatment with COPEGUS in combination with PEGASYS see also the PEGASYS Medication Guide ; if you have any of the following medical conditions: mental health problems, such as depression or anxiety: COPEGUS and PEGASYS combination therapy may make them worse. Tell your healthcare provider if you are being treated or had treatment in the past for any mental problems, including depression, thoughts of ending your life suicidal thoughts ; or a feeling of loss of contact with reality, such as hearing voices or seeing things that are not there psychosis ; . Tell your healthcare provider if you take any medicines for these problems. high blood pressure, heart problems or have had a heart attack. COPEGUS may worsen heart problems such as high blood pressure, increased heart rate, and chest pain. Tell your healthcare provider if you have or had a heart problem. Patients who have had certain heart problems should not take COPEGUS. blood disorders, including anemia low red blood cell count ; , thalassemia Mediterranean anemia ; and sickle-cell anemia. COPEGUS can reduce the number of red blood cells you have. This may make you feel dizzy or weak and could worsen any heart problems you might have. kidney problems. If your kidneys do not work properly, you may have worse side effects from COPEGUS treatment and require a lower dose. liver problems other than hepatitis C virus infection ; . organ transplant, and you are taking medicine that keeps your body from rejecting your transplant suppresses your immune system ; . thyroid disease. COPEGUS and PEGASYS combination therapy may make your thyroid disease worse or harder to treat. COPEGUS and PEGASYS treatment may be stopped if you develop thyroid problems that cannot be controlled by medicine. have or had drug or alcohol addiction or abuse. cancer.

Copegus side Patients should be advised that laboratory evaluations are required before starting therapy and periodically thereafter see Laboratory Tests ; . Patients should be instructed to remain well hydrated , especially during the initial stages of treatment. Patients should be advised to take COPEGUS with food. It made me feel like there was a list that you went down and saw surgery listed and said, yeah. Cautions about breastfeeding, infant formulas despite the benefits, not every mother is able to breast-feed or chooses to do so.

Copegus no prescription I think that hoffman-laroche is to be commended for coming tothe committee and bringing to the agency such a thorough and extensiveapplication and evaluation of their combination of pegasys, copegus for thetreatment of patients with hepatitis c infection and then lastly, thisreview was a joint effort between numerous individuals from the center fordrug evaluation and research and the center for biologics evaluation andresearch, brought together experts from a number of different disciplineswho came together in this collaborative effort to review this applicationand those people are all too numerous to tell you all their names, but iwant to thank everybody for all their hard work and with that i would liketo then just introduce emanuel petricoin who will bring to you someintroductory comments about this application. PENICILLINS amoxicillin ampicillin AUGMENTIN, -XR [G] dicloxacillin sodium penicillin V potassium CEPHALOSPORINS cefaclor cefadroxil CEFTIN SUSPENSION cefuroxime cephalexin MACROLIDE ANTIBIOTICS clindamycin erythromycin base erythromycin estolate erythromycin ethylsuccinate erythromycin stearate ZITHROMAX FLUOROQUINOLONES AVELOX, -ABC CIPRO, -XR TETRACYCLINES doxycycline hyclate minocycline tetracycline AMINOGLYCOSIDES neomycin sulfate SULFONAMIDES GANTRISIN SUSPENSION sulfadiazine sulfisoxazole ~ ANTIMYCOBACTERIAL AGENTS isoniazid MYAMBUTOL MYCOBUTIN pyrazinamide RIMACTANE ANTIFUNGALS ANCOBON DIFLUCAN GRIFULVIN V GRIS-PEG ketoconazole nystatin SPORANOX VFEND INJ. ; ANTIVIRAL Note: All oral antiviral drugs for the treatment of HIV infection are covered. acyclovir COPEGUS HEPSERA PEGASYS INJ. ; REBETRON INJ. ; TAMIFLU VALCYTE ANTIMALARIAL chloroquine phosphate DARAPRIM HALFAN hydroxychloroquine sulfate MALARONE mefloquine quinine sulfate ANTHELMINTIC mebendazole MINTEZOL MISC. ANTIINFECTIVES ALINIA clindamycin dapsone erythromycin sulfisoxazole MEPRON metronidazole NEBUPENT trimethoprim trimethoprim sulfamethoxazole VANCOCIN ZYVOX ANTINEOPLASTIC AGENTS Note: Oral antineoplastics are considered formulary, unless available generically. cyclophosphamide flutamide hydroxyurea leucovorin calcium megestrol acetate methotrexate tamoxifen thioguanine norethindrone - ethinyl estradiol norethindrone - mestranol norgestrel - ethinyl estradiol PROGESTINS medroxyprogesterone PROMETRIUM ANTIDIABETICS acetohexamide AVANDIA glipizide glucagon INJ. ; GLUCOVANCE * glyburide HUMALOG HUMULIN LANTUS metformin PRECOSE STARLIX tolazamide tolbutamide THYROID levothyroxine LEVOXYL propylthiouracil ~ THYROLAR UNITHROID MISC. ENDOCRINE ACTONEL CARNITOR INJ. ; CYTADREN DDAVP [G] DIDRONEL EVISTA FORTEO INJ. ; METHERGINE ORFADIN SOMAVERT STIMATE FERTILITY REGULATORS Coverage based on benefit design ; BRAVELLE INJ. ; CETROTIDE INJ. ; chorionic gonadotropin INJ. ; clomiphene citrate FOLLISTIM ANTAGON INJ. ; REPRONEX SUPPRELIN INJ. ; GROWTH HORMONES Coverage based on benefit design ; NUTROPIN, -AQ, -DEPOT INJ. ; PROTROPIN INJ and epivir-hbv! Table 1-1. Drug List and Data Reporting Levels for Hepatitis C .10 Table 10-1. Key Sources for Epidemiology Estimates--Hepatitis C Virus .103 Table 10-2. HCV Genotype Distributions Among the HCV Prevalent Population, Based on Survey Results 106 Table 10-3. HCV Genotype Distributions Amongst the HCV Prevalent Population, Europe and Japan 106 Figure 2-1. Treatment Algorithm for Hepatitis C .13 Figure 3-1. Lines of Therapy in Newly Diagnosed Hepatitis C Patients 20 Figure 3-2. Percentage of Hepatitis C Disease Patients on Each Line of Therapy Within One Year of Diagnosis 21 Figure 3-3. Polypharmacy Levels Within Lines of Therapy in Hepatitis C 22 Figure 3-4. Share of First-Line Therapy by Drug Class in Hepatitis C .23 Figure 3-5. Share of First-Line Therapy by Leading Agents in Hepatitis C .23 Figure 3-6. Combination vs. Monotherapy Use for First-Line Agents in Hepatitis C .25 Figure 3-7. Duration of First-Line Therapy Before Progression to Second-Line Therapy in Hepatitis C 26 Figure 3-8. Rate at Which Patients on First-Line Therapy Progress to Second-Line Therapy in Hepatitis C .27 Figure 3-9. Share of Second-Line Therapy by Drug Class in Hepatitis C .28 Figure 3-10. Share of Second-Line Therapy by Leading Agents in Hepatitis C .28 Figure 3-11. Rate at Which Patients on Second-Line Therapy Progress to Third-Line Therapy in Hepatitis C .29 Figure 3-12. Duration of Second-Line Therapy Before Progression to Third-Line Therapy in Hepatitis C .30 Figure 3-13. Share of Third-Line Therapy by Drug Class in Hepatitis C .31 Figure 3-14. Share of Third-Line Therapy by Leading Agents in Hepatitis C .31 Figure 4-1. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Intron A .33 Figure 4-2. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Pegasys .34 Figure 4-3. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Peg-Intron 35 Figure 4-4. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Infergen 36 Figure 4-5. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Generic Ribavirin 37 Figure 4-6. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Copegks 38 Figure 4-7. Progression of Newly Diagnosed Hepatitis C Patients Through Treatment from Rebetol 39.

2-13 INHALED HUMAN INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Pulmonary delivery of insulin in type 2 diabetic patients who required insulin improved glycemic control, was well tolerated, and demonstrated no adverse pulmonary effects. Pulmonary administration still does not match the physiological passage of insulin through the liver. Practical point: This application requires much more experience and exelon.

Where 1 and 2 are the convex weighting factors of C and R. Geng Chen [8] has used connectivity as the criteria to select a CH, where each node in k-hop neighborhood makes an equal contribution to C. However, we consider the difference of these neighbors based on the location and the capability. So we define connectivity C as in and mysoline. CHC Combination Therapy Study NV15801 Body System PEGASYS 180 g + 1000 mg or 1200 mg COPEGUS 48 week N 451 % Neurological Headache Dizziness excluding vertigo ; Memory impairment Psychiatric Irritability Anxiety Nervousness Insomnia Depression Concentration impairment Mood alteration Resistance Mechanism Disorders Overall Respiratory, Thoracic and Mediastinal Dyspnea Cough Dyspnea exertional Skin and Subcutaneous Tissue Alopecia Pruritus Dermatitis Dry skin Rash Sweating increased Eczema Visual Disorders Vision blurred 5 2 * Described as Study 4 in the PEGASYS Package Insert. * Severe hematologic abnormalities lymphocyte 0.5 x 109 L; hemoglobin 10 g dL; neutrophil 0.75 x 109 L; platelet 50 x 109 L ; . 28 Intron A + 1000 mg or 1200 mg REBETOL 48 week N 443. Children' responses to parents with MS s Title: Emotional responses of children and adolescents to parents with multiple sclerosis. Authors: R Yahav, J Vosburgh & A Miller. Place of Report: Haifa, Israel. Journal Reference: Multiple Sclerosis, 2005. Vol. 11, pages 464-468. Research Summary The effects of long-term illnesses on children and adolescents and the family unit ; is extremely complex and is dependant on the interactions of many different factors. These include the child' personal experiences of the illness, s the quality of the relationship between the parent and child and how the family functions as a whole. There is currently little research available on what bearing a parent having MS has on a child. This study investigated the impact of having one parent with MS, on a child' emotions and behaviours. s 56 children ages 10-18 ; , each with a parent with MS living with them, were interviewed. A further 156 children, with parents who did not have MS were also interviewed, as a comparison. Children were asked about their levels of fear, anxiety and anger in their situation. They were asked whether they felt an increased sense of responsibility or personal concern towards the parent with MS. Questions also covered the burden of tasks and errands at home. Children were asked whether they gave priority to a parent over their own needs e.g. giving up meeting friends to look after the parent ; , known as " yielding behaviour" . Results showed that children with a parent with MS exhibited significantly greater concern for their parents and a greater degree of yielding behaviour and active protection for the parent. They had considerably greater levels of fear and anxiety for the parent' health as well as feelings of anger, than s children with unaffected parents. The task burden at home was also reported to be greater. Further analysis showed that daughters reported a greater and oxytrol. PEGASYS alone or in combination with COPEGUS causes a broad variety of serious adverse reactions see BOXED WARNING and WARNINGS ; . The most common life-threatening or fatal events induced or aggravated by PEGASYS and COPEGUS were depression, suicide, relapse of drug abuse overdose, and bacterial infections, each occurring at a frequency of.cl %. Hepatic decompensation occurred in 2% 10 574 ; of CHC HIV patients see WARNINGS. Applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Teressa Jesus Rodriguez, Applicant for Technician Registration No. 129460. Alleged violations: convictions for the misdemeanor offense of Driving While Intoxicated. Agreed Board Order accepted by applicant and entered by the Board on 2-8-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Glenn Raymond Archer, Applicant for Technician Registration No. 127162. Alleged violations: convictions for the misdemeanor offense of Driving While Intoxicated. Agreed Board Order accepted by applicant and entered by the Board on 2-8-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Salvador Morales Gutierrez, Applicant for Technician Registration No. 128397. Alleged violations: convictions for the misdemeanor offense of Driving While Intoxicated. Agreed Board Order accepted by applicant and entered by the Board on 28-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Larry Spears, Sr., Applicant for Technician Registration No. 129425. Alleged violations: convictions for the misdemeanor offense of Driving While Intoxicated. Agreed Board Order accepted by applicant and entered by the Board on 2-8-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Kevin Patrick Williams, Applicant for Technician Registration No. 128688. Alleged violations: received deferred adjudication for the misdemeanor offense of Possession of Marijuana. Agreed Board Order accepted by applicant and entered by the Board on 2-8-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not physiologically or psychologically alcohol or drug dependent and is able to perform technician duties without posing a threat to the public; if registration is granted, registration will be placed on probation for 5 years with conditions. Gilberto Adrian Hernandez, Applicant for Technician Registration No. 129758. Alleged violations: two alcohol-related misdemeanor convictions. Agreed Board Order accepted by applicant and entered by the Board on 5-10-06: pharmacy technician registration granted if mental health professional provides written documentation which states that applicant is not and topamax. This information will help your doctor and you decide whether you should use PEGASYS RBV combination therapy and what extra care may need to be taken while you are on these medicines. If you have any doubts about your health condition or about taking PEGASYS RBV, talk to your doctor. INTERACTIONS WITH THIS MEDICATION Drugs that may interact with PEGASYS RBV include: didanosine, lamivudine, methadone, sho-saiko-to Xiao-ChaiHu, stavudine, theophylline, zidovudine. PROPER USE OF THIS MEDICATION Usual dose: How should you take PEGASYS RBV combination therapy? Your doctor has prescribed PEGASYS RBV combination therapy after carefully studying your case. Other people may not benefit from taking this medicine, even though their problems may seem similar to yours. Do not give your medicine to anyone else. PEGASYS is given as an injection just under the skin, on the stomach or thighs. You may hear people call this type of injection a "subcutaneous" or "Sub Q" injection. This means that the injection goes into the layer of fat just under the skin. If you have any questions about how to take PEGASYS or have trouble giving yourself the injections, call your doctor immediately. Your healthcare provider will tell you how much medicine to take and how often to take it. PEGASYS is a ready-to-use solution usually given as a single injection once per week. Make sure that you drink plenty of fluids while you are being treated with PEGASYS. PEGASYS is supplied in two different ways: pre-filled syringes and vials. It is important that you follow the specific instructions for using the kind of PEGASYS that your doctor has prescribed. Whether you give yourself the injection, or another person gives the injection to you, it is important to follow the instructions see Appendix 1- How to use ; in this information sheet. COPEGUS tablets should be taken each day in two doses with food morning and evening ; . Your healthcare provider will determine the correct dose of COPEGUS tablets based on your weight and the genotype of the disease you have. Do not take COPEGUS alone to treat hepatitis C virus infection. COPEGUS does not treat hepatitis C virus infections by itself. COPEGUS should be used in combination with PEGASYS to treat continuing chronic ; hepatitis C virus infections. How long will you have to take PEGASYS RBV? Your doctor will tell you how long you need to use PEGASYS RBV. Over time, your doctor may change your dose of PEGASYS RBV.

Quality of Life Assessment During treatment with interferon alfa-2a, patients commonly experience shaking chills, body aches, headache, loss of concentration, fatigue, anxiety, and insomnia. Such complaints reflect the significant quality of life reductions associated with standard interferon alfa-2a therapy. In NV15497, patients treated with PEGASYS experienced superior quality of life during the first 12 weeks of therapy than those receiving standard interferon alfa-2a. Most of these differences were statistically and clinically significant in terms of physical health, mental health and fatigue severity. Combination Therapy Patients with elevated ALT levels The safety and effectiveness of PEGASYS in combination with ribavirin COPEGUS ; for the treatment of hepatitis C were assessed in two prospective, randomised controlled, multinational clinical trials NV15942 and NV15801 ; . All patients were adults with compensated CHC, detectable HCV RNA, persistently elevated ALT levels, a histological diagnosis consistent with CHC, and previously untreated with interferon and or ribavirin. Approximately 20% of patients in both studies had compensated cirrhosis. In NV15942, a prospective, randomised controlled, multinational clinical trial, 1284 patients received PEGASYS 180 g sc qw and randomised to treatment for either 24 or 48 weeks and to a COPEGUS daily dose of 800 mg or 1000 1200 mg for body weight 75 kg 75 Assignment to the four treatment arms was stratified by viral genotype and baseline HCV viral titer. In NV15801, a prospective, randomised controlled, multinational clinical trial, 1121 patients received either PEGASYS 180 g sc qw with placebo, PEGASYS 180 g sc qw with COPEGUS 1000 mg body weight 75kg ; or 1200 mg body weight 75kg ; , or interferon alfa-2b 3 MIU sc tiw with ribavirin 1000 mg or 1200 mg daily REBETRON ; for 48 weeks of therapy followed by 24 weeks of treatment-free follow-up. Ribavirin or placebo treatment assignment was blinded. Sustained virological response was defined as a single undetectable HCV RNA measurement at the end of the treatment-free follow-up period, measured by the qualitative COBAS AMPLICOR HCV test, version 2.0 lower limit of detection 100 copies ml equivalent to 50 IU ml and atrovent and Order copegus. Advice to Athletes, Coaches and Team Management 1. All athletes, coaches and team management shall, as a condition of participation, sign a declaration that they are aware of the WSF Policy on Doping and all related rules and regulations. Member countries are advised to take every measure to ensure that their athletes, coaches and team management are aware of and understand the rules with regard to doping control. Athletes should be notified of their responsibility to check if any medication that they propose taking, whether purchased or prescribed, contains a banned substance. It should be pointed out that not all Medical Practitioners will be aware of the latest banned substances or products containing them. A checklist of commonly used drugs and medications, which are permissible from the doping control point of view, will be circulated to all Member countries. A comprehensive and up-to-date checklist will be available from the WSF; anything which does not appear in the list should be checked with the WSF. The athlete should be told that if in doubt, he she should: a ; Seek written confirmation from the WSF whether the substance or product is on the permitted IOC list; If it is not, the Member country should contact the WSF quoting the name of the substance and or product.

PEGASYS The recommended dose of PEGASYS monotherapy is 180 g 1.0 ml vial or 0.5 ml prefilled syringe ; once weekly for 48 weeks by subcutaneous administration in the abdomen or thigh. PEGASYS and COPEGUS Combination The recommended dose of PEGASYS when used in combination with ribavirin is 180 g 1.0 ml vial or 0.5 ml prefilled syringe ; once weekly. The recommended dose of COPEGUS and duration for PEGASYS COPEGUS therapy is based on viral genotype see Table 6 ; . The daily dose of COPEGUS is 800 mg to 1200 mg administered orally in two divided doses. The dose should be individualized to the patient depending on baseline disease characteristics e.g., genotype ; , response to therapy, and tolerability of the regimen. Since COPEGUS absorption increases when administered with a meal, patients are advised to take COPEGUS with food. Table 6 Genotype Genotypes 1, 4 Genotypes 2, 3 PEGASYS and COPEGUS Dosing Recommendations PEGASYS Dose COPEGUS Dose Duration 75 kg 1000 mg 180 g 75 kg 1200 mg 180 g 800 mg 48 weeks 24 weeks 48 weeks.

Copegus information